NCT01358708View on ClinicalTrials.gov

Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg

PHASE3TerminatedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Diarrhea-predominant Irritable Bowel Syndrome
Interventions
DRUG

LACTEOL® 340 mg

LACTEOL® 340 mg will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.

DRUG

PLACEBO

Matched LACTEOL® 340 mg Placebo will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.

Trial Locations (8)

Unknown

Bordeaux

Colombes

Marseille

Nice

Rouen

Berlin

Hamburg

Mannheim

Sponsors
All Listed Sponsors
lead

Forest Laboratories

INDUSTRY

NCT01358708 - Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg | Biotech Hunter | Biotech Hunter